Telomir Pharmaceuticals, Inc. (TELO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TELO currently has 31.7M outstanding shares. with limited dilution risk as only 1.2M additional shares (3.8%) are authorized for issuance. The company has minimally diluted shareholders by 7.06% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 17, 2026 |
10-K filing | 31.7M shares outstanding |
32M | 1.2M |
| Sep 04, 2025 |
8-K filing: Telomir Pharmaceuticals, Inc. completed the sale of 1,550,000 shares of its common stock at an average price of $1.87 per share, resulting in gross proceeds of approximately $2.9 million. ($2.9M proceeds) |
30M | 1.2M |
| Aug 14, 2025 |
10-Q filing | 30.0M shares outstanding |
30M | 1.2M |
| Jul 22, 2025 |
8-K filing: Telomir Pharmaceuticals, Inc. sold 1,100,000 shares of its common stock at an average price of $2.6045 per share in block sales to institutional investors, with gross proceeds totaling approximately $2.9 million. ($2.9M proceeds) |
30M | 1.2M |
| May 21, 2025 |
8-K filing: Telomir Pharmaceuticals secures $3 million through a direct stock investment by The Bayshore Trust, issuing 1 million restricted common shares at $3.00 per share. ($3.0M proceeds) |
30M | 1.2M |
| May 14, 2025 |
10-Q filing | 29.8M shares outstanding |
30M | 1.2M |
| Feb 14, 2025 |
S-3 filing: Telomir Pharmaceuticals files an S-3 registration statement to offer common stock, preferred stock, warrants and/or units for general corporate purposes. |
30M | 1.2M |
| Feb 04, 2025 |
10-K filing | 29.5M shares outstanding |
30M | 1.2M |
| Dec 11, 2024 |
8-K filing: Telomir Pharmaceuticals issued 142,857 shares of common stock at $7 per share to an accredited investor for gross proceeds of $1 million. ($1.0M proceeds) |
30M | 1.2M |
| Nov 12, 2024 |
10-Q filing | 29.6M shares outstanding |
30M | 1.2M |
| Aug 13, 2024 |
10-Q filing | 29.6M shares outstanding |
30M | 1.2M |
| May 13, 2024 |
10-Q filing | 27.8M shares outstanding |
28M | 1.2M |
| Mar 29, 2024 |
10-K filing | 29.0M shares outstanding |
29M | 1.2M |
| Feb 13, 2024 |
8-K filing: Telomir Pharmaceuticals, Inc. closed an underwritten public offering of 1,000,000 shares of common stock at $7.00 per share on February 13, 2024, resulting in gross proceeds of $7,000,000, and issued warrants to Kingswood to purchase 50,000 shares of common stock at an exercise price of $7.00 per share. ($7.0M proceeds) |
29M | 1.2M |
| Jan 03, 2024 |
S-1/A filing: This S-1/A filing describes the initial public offering of 1,000,000 shares of common stock of Telomir Pharmaceuticals, Inc. at an assumed initial public offering price of $7.00 per share. |
29M | 1.2M |
| Dec 14, 2023 |
S-1/A filing: Initial public offering of 1,000,000 shares of common stock of Telomir Pharmaceuticals, Inc. at an assumed initial public offering price of $7.00 per share. |
29M | 1.2M |
| Nov 14, 2023 |
S-1 filing: Telomir Pharmaceuticals, Inc. is initiating an initial public offering of common stock and is planning to list on the Nasdaq Capital Market under the symbol "TELO". |
N/A | 0 |